Chugai Pharmaceutical Co., Ltd. Website

Chugai Pharmaceutical Co., Ltd.

TSE-4519

Basic

  • Market Cap

    ¥8,149.24B

  • EV

    ¥7,384.67B

  • Shares Out

    1,645.31M

  • Revenue

    ¥1,036.08B

  • Employees

    7,604

Margins

  • Gross

    67.67%

  • EBITDA

    45.59%

  • Operating

    42.54%

  • Pre-Tax

    42.86%

  • Net

    31.5%

  • FCF

    31.46%

Returns (5Yr Avg)

  • ROA

    19.54%

  • ROTA

    24.72%

  • ROE

    24.17%

  • ROCE

    32.74%

  • ROIC

    32.34%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥5,932.14

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    ¥764.57B

  • Net Debt

    -¥764.57B

  • Debt/Equity

    0.01

  • EBIT/Interest

    20,034.14

Growth (CAGR)

  • Rev 3Yr

    10.1%

  • Rev 5Yr

    12.05%

  • Rev 10Yr

    8.52%

  • Dil EPS 3Yr

    15.71%

  • Dil EPS 5Yr

    26.76%

  • Dil EPS 10Yr

    18.24%

  • Rev Fwd 2Yr

    0.73%

  • EBITDA Fwd 2Yr

    3.96%

  • EPS Fwd 2Yr

    5.75%

  • EPS LT Growth Est

    6.05%

Dividends

  • Yield

  • Payout

    40.33%

  • DPS

    ¥80

  • DPS Growth 3Yr

    13.3%

  • DPS Growth 5Yr

    22.78%

  • DPS Growth 10Yr

    18.22%

  • DPS Growth Fwd 2Yr

    4.97%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

588,896

633,314

802,836

1,039,247

974,493

887,442

Other Revenues, Total

97,288

153,632

196,923

220,699

136,874

148,634

Total Revenues

686,184

786,946

999,759

1,259,946

1,111,367

1,036,076

Total Revenues % Chg.

18.4%

14.7%

27%

26%

-11.8%

-14.5%

Cost of Goods Sold, Total

266,071

273,465

338,147

476,251

413,306

334,927

Gross Profit

420,113

513,481

661,612

783,695

698,061

701,149

Selling General & Admin Expenses, Total

101,574

94,401

102,416

100,760

112,580

114,150

R&D Expenses

107,942

117,850

137,299

149,626

174,868

173,356

Other Operating Expenses

-28,561

-27,108

Other Operating Expenses, Total

209,516

212,251

239,715

250,386

258,887

260,398

Operating Income

210,597

301,230

421,897

533,309

439,174

440,751

Interest Expense, Total

-125

-62

-48

-61

-27

-22

Interest And Investment Income

545

52

4,674

3,318

Net Interest Expenses

420

-62

-48

-9

4,647

3,296

Currency Exchange Gains (Loss)

Other Non Operating Income (Expenses)

-3,124

-2,980

-2,464

-2,134

2

EBT, Excl. Unusual Items

207,893

298,188

419,385

531,166

443,821

444,049

Asset Writedown

EBT, Incl. Unusual Items

207,893

298,188

419,385

531,166

443,821

444,049

Income Tax Expense

50,333

83,455

116,390

156,737

118,349

117,676

Earnings From Continuing Operations

157,560

214,733

302,995

374,429

325,472

326,373

Minority Interest

Net Income

157,560

214,733

302,995

374,429

325,472

326,373

Net Income to Common Incl Extra Items

157,560

214,733

302,995

374,429

325,472

326,373

Net Income to Common Excl. Extra Items

157,560

214,733

302,995

374,429

325,472

326,373

Total Shares Outstanding

1,642.6

1,643.9

1,644.3

1,645

1,645.3

1,645.4

Weighted Avg. Shares Outstanding

1,642.1

1,643.4

1,644.2

1,644.8

1,645.2

1,645.3

Weighted Avg. Shares Outstanding Dil

1,644.5

1,645.1

1,645.2

1,645.3

1,645.5

1,645.6

EPS

95.9

130.7

184.3

227.6

197.8

198.4

EPS Diluted

95.8

130.5

184.2

227.6

197.8

198.3

EBITDA

236,998

331,606

452,765

564,743

470,914

472,391

Effective Tax Rate

24.2%

28%

27.8%

29.5%

26.7%

26.5%